Detection, control, and management of a respiratory syncytial virus outbreak in a pediatric hematology-oncology department.

Background:Immunocompromised patients are at increased risk for severe respiratory syncytial virus (RSV) infection. Palivizumab is approved for prevention of RSV in specific populations but not for treatment. Few studies demonstrated the safety and successful treatment with intravenous (IV) palivizu